Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CGON filed a notice of proposed sale of restricted or control securities. The filing covers the planned sale of 13,109 common shares, with an aggregate market value of $549,660.37, through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/09/2026. The issuer had 80,666,179 common shares outstanding. The shares to be sold were acquired on 01/09/2026 by exercising stock options granted by the issuer, paid for in cash on the same date.
CG Oncology reported new clinical timing and data for its bladder cancer programs. The company now expects topline Phase 3 PIVOT-006 data in the first half of 2026 for intermediate-risk non–muscle invasive bladder cancer, a U.S. population estimated at over 50,000 patients. Updated BOND-003 Cohort P results for cretostimogene monotherapy in BCG-unresponsive papillary-only disease showed Kaplan-Meier high-grade event-free survival of 95.7%, 84.6% and 80.4% at 3, 6 and 9 months in 51 evaluable patients, with no Grade 3 or higher treatment-related adverse events, no radical cystectomies and no progression to muscle-invasive disease. First results from CORE-008 Cohort A in high-risk, BCG-naïve patients with CIS showed an overall complete response rate of 83.7% (41 of 49), including 79.2% with the original administration and 88.0% with an optimized two-step administration, with mostly low-grade, bladder-localized adverse events and no related serious or Grade 3+ events.
CG Oncology, Inc. (CGON) disclosed a new stock option grant to a director. On 11/24/2025, the reporting person received a director stock option to purchase 20,889 shares of CG Oncology common stock at an exercise price of $43.56 per share. The option expires on 11/23/2035 if not exercised.
According to the vesting terms, 1/36th of the shares subject to the option vest monthly following November 24, 2025, as long as the director continues to provide service to the company through each vesting date. After this grant, the reporting person beneficially owns 20,889 derivative securities directly in the form of these stock options.
CG Oncology, Inc. (CGON) director Christina Rossi has filed an initial insider ownership report indicating that she currently beneficially owns no securities of the company. Both the non-derivative and derivative security tables show no holdings, and the explanation section explicitly states that no securities are beneficially owned.
CG Oncology, Inc. appointed Christina Rossi to its Board of Directors, effective November 24, 2025, as a Class II director with a term running until the 2026 annual meeting of stockholders. Her compensation follows the company’s standard non-employee director program, including an annual cash fee of $45,000, paid quarterly, and an initial grant of 20,889 stock options that vest in equal monthly installments over three years, contingent on her continued service.
The company also reported that Simone Song resigned from the Board and all committees on November 22, 2025, effective immediately. The company stated that her resignation was not due to any disagreement with CG Oncology. Ms. Song had been a member of the Audit Committee and chair of the Compensation Committee.
CG Oncology, Inc. (CGON) filed a Form 3 reporting that its Interim Principal Financial and Accounting Officer, James M. DeTore, currently holds no beneficial ownership of the company’s securities. The filing identifies him as an officer of CG Oncology and confirms that no non-derivative or derivative securities are reported as beneficially owned. The Form 3 is filed by a single reporting person and serves as an initial ownership statement required under securities regulations.
CG Oncology, Inc. (CGON) director Leonard Post reported a small insider transaction involving company stock. On 11/17/2025, he exercised a director stock option to acquire 1,000 shares of common stock at an exercise price of $0.6 per share, then sold those 1,000 shares of common stock at a price of $41.43 per share. After these transactions, he reported owning 0 shares of common stock directly.
Following the option exercise, he continued to hold 117,077 derivative securities in the form of stock options, which are exercisable until 07/08/2028 and are fully vested. The filing notes that the sale was carried out under a Rule 10b5-1 trading plan that Leonard Post adopted on September 6, 2024, indicating the trades were pre-arranged under that plan.
CG Oncology (CGON) announced a finance leadership transition. Interim principal financial and accounting officer Robert Lapetina resigned effective November 30, 2025. The company appointed Jim DeTore as interim principal financial and accounting officer effective November 17, 2025, via a Consulting Agreement with Monomoy Advisors, LLC.
The agreement pays Monomoy Advisors $32,000 for November 2025 (prorated for a partial month) and $64,000 for each month thereafter, with a minimum three‑month term and an option to extend for an additional three months. Either party may terminate for a material breach not cured within 30 days of notice or for any reason with 60 days’ prior written notice.
DeTore previously served as CFO at Neurogastrx (June 2021–June 2025), Proteostasis Therapeutics (August 2016–February 2017), and Bluebird Bio (November 2014–February 2016), and consulted for biotech and pharma companies. He is eligible for the company’s standard indemnification agreement, and there are no disclosable related‑party transactions.
CG Oncology, Inc. filed its Q3 2025 report, showing total revenues of $1.666 million and a net loss of $43.808 million for the quarter. Operating costs were driven by research and development $27.884 million and general and administrative $23.334 million, offset by interest income $7.321 million.
Liquidity remains strong with approximately $680.3 million of cash, cash equivalents and marketable securities and working capital ~$665.3 million as of September 30, 2025. Under its at‑the‑market program, the company sold 1,515,151 shares at $33.00 for net proceeds $48.7 million in Q3, and subsequently sold 2,343,967 shares for net proceeds $98.4 million after quarter‑end.
CG Oncology consolidated Biovire following a July 2025 conversion event, recognizing $12.805 million of goodwill and $1.700 million in intangible assets; the total consideration was $26.844 million. The company reported positive clinical updates for cretostimogene, including a 24‑month complete response rate of 41.8% (46/110) in BOND‑003 Cohort C and initiated its BLA submission in Q4 2025. In litigation, a jury verdict favored the company regarding ANI’s claims, with no damages and no 5% royalty owed.
CG Oncology (CGON) furnished an update on its financial results under Item 2.02. The company announced it issued a press release covering results for the quarter ended September 30, 2025, which is attached as Exhibit 99.1.
The company states the information in this report, including Exhibit 99.1, is being furnished and not filed pursuant to General Instruction B.2. The filing also lists the company’s common stock on The Nasdaq Global Select Market under the symbol CGON.